Association of CD14 with incident dementia and markers of brain aging and injury
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective To test the hypothesis that the inflammatory marker plasma soluble CD14 (sCD14) associates with incident dementia and related endophenotypes in 2 community-based cohorts.
Methods Our samples included the prospective community-based Framingham Heart Study (FHS) and Cardiovascular Health Study (CHS) cohorts. Plasma sCD14 was measured at baseline and related to the incidence of dementia, domains of cognitive function, and MRI-defined brain volumes. Follow-up for dementia occurred over a mean of 10 years (SD 4) in the FHS and a mean of 6 years (SD 3) in the CHS.
Results We studied 1,588 participants from the FHS (mean age 69 ± 6 years, 47% male, 131 incident events) and 3,129 participants from the CHS (mean age 72 ± 5 years, 41% male, 724 incident events) for the risk of incident dementia. Meta-analysis across the 2 cohorts showed that each SD unit increase in sCD14 was associated with a 12% increase in the risk of incident dementia (95% confidence interval 1.03–1.23; p = 0.01) following adjustments for age, sex, APOE ε4 status, and vascular risk factors. Higher levels of sCD14 were associated with various cognitive and MRI markers of accelerated brain aging in both cohorts and with a greater progression of brain atrophy and a decline in executive function in the FHS.
Conclusion sCD14 is an inflammatory marker related to brain atrophy, cognitive decline, and incident dementia.
Glossary
- 3MSE=
- Modified Mini-Mental State Examination;
- Aβ=
- β-amyloid;
- AD=
- Alzheimer disease;
- CD14=
- cluster of differentiation 14;
- CHS=
- Cardiovascular Health Study;
- CI=
- confidence interval;
- CRP=
- C-reactive protein;
- CVD=
- cardiovascular disease;
- DSM-IV=
- Diagnostic and Statistical Manual of Mental Disorders, 4th edition;
- DSST=
- Digit Symbol Substitution Test;
- FHS=
- Framingham Heart Study;
- FLAIR=
- fluid-attenuated inversion recovery;
- HR=
- hazard ratio;
- IL-6=
- interleukin 6;
- mCD14=
- membrane-bound cluster of differentiation 14;
- MMSE=
- Mini-Mental State Examination;
- NSAID=
- nonsteroidal anti-inflammatory drug;
- sCD14=
- soluble cluster of differentiation 14;
- SPGR=
- spoiled gradient-recalled echo;
- WMHV=
- white matter hyperintensity volume
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
↵* These authors contributed equally as co–first authors.
↵† These authors contributed equally as co–senior authors.
- Received January 22, 2019.
- Accepted in final form July 18, 2019.
- © 2019 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Insulin-like growth factor-1 and risk of Alzheimer dementia and brain atrophyAndrew J. Westwood, Alexa Beiser, Charles DeCarli et al.Neurology, April 04, 2014 -
Articles
No advantage of Aβ42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studiesC. A. Szekely, R. C. Green, J.C.S. Breitner et al.Neurology, May 28, 2008 -
Article
Sleep architecture and the risk of incident dementia in the communityMatthew P. Pase, Jayandra J. Himali, Natalie A. Grima et al.Neurology, August 23, 2017 -
Articles
NSAID use and dementia risk in the Cardiovascular Health Study*Role of APOE and NSAID typeC. A. Szekely, J.C.S. Breitner, A. L. Fitzpatrick et al.Neurology, November 14, 2007